BillionToOne delivered a strong fourth quarter with 113% revenue growth and a successful transition to GAAP profitability. The company saw significant expansion in its oncology segment and improved gross margins to 71%, leading to a raise in its full-year 2026 revenue guidance.

BillionToOne achieved profitability in Q3 2025 with $83.5M in revenue, $1.5M in net income, and $9.6M in operating income, supported by strong growth in prenatal and oncology testing.